Literature DB >> 1285134

The epidemiology of pertussis in England and Wales.

E Miller, J E Vurdien, J M White.   

Abstract

Recovery in the uptake of whole-cell pertussis vaccine from 30% in 1978 to 91% in 1992 has resulted in a major reduction in the incidence of pertussis and in the proportion of cases occurring in pre-school children. This has been accompanied by a decline in pertussis mortality rates, with no deaths reported since September 1990. Seventy-four per cent of the 50 fatal cases reported since 1980 have been infants under one year of age, demonstrating the importance of completing primary immunisation as early as possible after birth. There is no evidence, as yet, that introduction of the accelerated immunisation schedule in June 1990 has reduced the proportion of cases occurring in infants, suggesting that the decline in mortality during the last two years is largely due to indirect protection provided by the current high level of vaccine-induced herd immunity. If 90% coverage is sustained and there is no significant waning of immunity with age, the circulation of Bordetella pertussis should be sufficiently reduced to interrupt the four year epidemic cycle for the first time in the United Kingdom. The hypothesis that vaccine-induced immunity has a serotype-specific component is supported by recent changes in serotype prevalence which have followed the increase in vaccine coverage. Given the successful reinstatement of whole-cell vaccine in the UK immunisation programme, the case for replacing it with a new acellular preparation will require careful evaluation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285134

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  9 in total

1.  Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.

Authors:  David J Litt; Shona E Neal; Norman K Fry
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

2.  Imperfect vaccine and hysteresis.

Authors:  Xingru Chen; Feng Fu
Journal:  Proc Biol Sci       Date:  2019-01-16       Impact factor: 5.349

3.  Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis.

Authors:  Johanna Mäkinen; Jussi Mertsola; Matti K Viljanen; Heikki Arvilommi; Qiushui He
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 4.  Acellular pertussis vaccines.

Authors:  E Miller
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

Review 5.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Symptoms and complications of pertussis in adults.

Authors:  S Postels-Multani; H J Schmitt; C H Wirsing von König; H L Bock; H Bogaerts
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

7.  Accelerating control of pertussis in England and Wales.

Authors:  Helen Campbell; Gayatri Amirthalingam; Nick Andrews; Norman K Fry; Robert C George; Timothy G Harrison; Elizabeth Miller
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

8.  Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?

Authors:  Audrey J King; Tamara van Gorkom; Han G J van der Heide; Abdolreza Advani; Saskia van der Lee
Journal:  BMC Genomics       Date:  2010-01-26       Impact factor: 3.969

Review 9.  Vaccine Adjuvants: from 1920 to 2015 and Beyond.

Authors:  Alberta Di Pasquale; Scott Preiss; Fernanda Tavares Da Silva; Nathalie Garçon
Journal:  Vaccines (Basel)       Date:  2015-04-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.